Tempe, Ariz.-based Clinical Research Advantage (CRA), a community-based network of clinical trial sites, has been named best clinical trial site network bythe World Vaccine Congress.

The award was announced at the 2012 Vaccine Industry Excellence Awards, which celebrate leaders, innovators and pioneers in the vaccine industry. CRA also received second place for Best Clinical Trial Site.

“We are honored to win this prestigious award,” said Mark Hanley, CEO of CRA. “The key to CRA’s success has been the development of research offices within community physician practices. We take pride in partnering with these established practices to provide rapid, successful enrollment that expedites the process of bringing vaccines to market.”

Casey Orvin, vice president of business development of CRA, added, “We are grateful to all the pharmaceutical sponsors and CROs who trust our sites and staff, time and time again, to successfully enroll in their vaccine studies. We have been fortunate, for the last several years, to be the leader in providing high quality data and rapidly enrolling sites to the vaccine industry.”

The Vaccine Industry Excellence Award nominees are voted on by an independent judging panel, comprised of senior industry representatives from public health organizations, non-governmental organizations, academic and research institutes, industry experts and affiliate member associations, pharmaceutical, biotech, global consultancies and press affiliates.